[1]
|
Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Heon, S. and Johnson, B.E. (2012) Adjuvant Chemotherapy for Surgically Resected Non-Small Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 144, S39-S42. https://doi.org/10.1016/j.jtcvs.2012.03.039
|
[3]
|
Datta, D. and Lahiri, B. (2003) Preoperative Evaluation of Patients Undergoing Lung Resection Surgery. Chest, 123, 2096-2103. https://doi.org/10.1378/chest.123.6.2096
|
[4]
|
Remon, J., et al. (2013) Adjuvant Treatment in Resected Non-Small Cell Lung Cancer: Current and Future Issues. Critical Reviews in Oncology/Hematology, 88, 375-386. https://doi.org/10.1016/j.critrevonc.2013.05.017
|
[5]
|
Osarogiagbon, R.U., et al. (2016) Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base. Journal of Thoracic Oncology, 11, e5-e16.
https://doi.org/10.1016/j.jtho.2015.08.002
|
[6]
|
Steger, V., et al. (2009) Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival. The Annals of Thoracic Surgery, 87, 1676-1683.
https://doi.org/10.1016/j.athoracsur.2009.03.068
|
[7]
|
庞书菊, 陈公琰. 表皮生长因子受体酪氨酸激酶抑制剂在可手术非小细胞肺癌新辅助及辅助治疗中的研究进展[J]. 肿瘤学杂志, 2021, 27(3): 175-179.
|
[8]
|
Zhou, C., et al. (2011) Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (Optimal, Ctong-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study. The Lancet Oncology, 12, 735-742. https://doi.org/10.1016/S1470-2045(11)70184-X
|
[9]
|
Rosell, R., et al. (2012) Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 13, 239-246. https://doi.org/10.1016/S1470-2045(11)70393-X
|
[10]
|
Wu, Y.L., et al. (2015) First-Line Erlotinib versus Gemcitabine/Cisplatin in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Analyses from the Phase III, Randomized, Open-Label, ENSURE Study. Annals of Oncology, 26, 1883-1889. https://doi.org/10.1093/annonc/mdv270
|
[11]
|
Mitsudomi, T., et al. (2010) Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial. The Lancet Oncology, 11, 121-128. https://doi.org/10.1016/S1470-2045(09)70364-X
|
[12]
|
Shi, Y.K., et al. (2017) First-Line Icotinib versus Cisplatin/Pemetrexed plus Pemetrexed Maintenance Therapy for Patients with Advanced EGFR Mutation-Positive Lung Adenocarcinoma (CONVINCE): A Phase 3, Open-Label, Randomized Study. Annals of Oncology, 28, 2443-2450. https://doi.org/10.1093/annonc/mdx359
|
[13]
|
Zhong, W.Z., et al. (2018) Gefitinib versus Vinorelbine plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC (ADJUVANT/CTONG1104): A Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 19, 139-148. https://doi.org/10.1016/S1470-2045(17)30729-5
|
[14]
|
Yue, D., et al. (2018) Erlotinib versus Vinorelbine plus Cisplatin as Adjuvant Therapy in Chinese Patients with Stage IIIA EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EVAN): A Randomised, Open-Label, Phase 2 Trial. The Lancet Respiratory Medicine, 6, 863-873. https://doi.org/10.1016/S2213-2600(18)30277-7
|
[15]
|
He, J., et al. (2021) Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II-IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 1021-1029. https://doi.org/10.1016/S2213-2600(21)00134-X
|
[16]
|
Xu, S.T., et al. (2019) The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). Journal of Thoracic Oncology, 14, 503-512.
https://doi.org/10.1016/j.jtho.2018.11.020
|
[17]
|
Shi, Y., et al. (2013) Icotinib versus Gefitinib in Previously Treated Advanced Non-Small-Cell Lung Cancer (ICOGEN): A Randomised, Double-Blind Phase 3 Non-Inferiority Trial. The Lancet Oncology, 14, 953-961.
https://doi.org/10.1016/S1470-2045(13)70355-3
|
[18]
|
He, Q., et al. (2021) Comparison of First-Generation EGFR-TKIs (Gefitinib, Erlotinib, And Icotinib) as Adjuvant Therapy in Resected NSCLC Patients with Sensitive EGFR Mutations. Translational Lung Cancer Research, 10, 4120-4129. https://doi.org/10.21037/tlcr-21-649
|
[19]
|
Zhang, Y., et al. (2014) Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE, 9, e107161. https://doi.org/10.1371/journal.pone.0107161
|
[20]
|
Kuan, F.C., et al. (2015) Overall Survival Benefits of First-Line EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small-Cell Lung Cancers: A Systematic Review and Meta-Analysis. British Journal of Cancer, 113, 1519-1528.
https://doi.org/10.1038/bjc.2015.356
|
[21]
|
Li, W.Q. and Cui, J.W. (2020) Non-Small Cell Lung Cancer Patients with ex19del or Exon 21 L858R Mutation: Distinct Mechanisms, Different Efficacies to Treatments. Journal of Cancer Research and Clinical Oncology, 146, 2329-2338.
https://doi.org/10.1007/s00432-020-03296-6
|
[22]
|
Peters, S., et al. (2016) The Impact of Brain Metastasis on Quality of Life, Resource Utilization and Survival in Patients with Non-Small-Cell Lung Cancer. Cancer Treatment Reviews, 45, 139-162.
https://doi.org/10.1016/j.ctrv.2016.03.009
|
[23]
|
Wu, Y.L., et al. (2018) CNS Efficacy of Osimertinib in Patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data from a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology, 36, 2702-2709.
https://doi.org/10.1200/JCO.2018.77.9363
|
[24]
|
Wu, Y.L., et al. (2020) Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 383, 1711-1723. https://doi.org/10.1056/NEJMoa2027071
|
[25]
|
Wu, Q., et al. (2021) First-Generation EGFR-TKI plus Chemotherapy versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 11, Article ID: 598265. https://doi.org/10.3389/fonc.2021.598265
|
[26]
|
Li, F., et al. (2021) No Benefit of Chemotherapy in Osimertinib-Treated Postoperative Non-Small Cell Lung Cancer Patients. Translational Lung Cancer Research, 10, 3689-3693. https://doi.org/10.21037/tlcr-21-640
|
[27]
|
Wen, M., et al. (2020) Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Oncology Research and Treatment, 43, 686-693. https://doi.org/10.1159/000506692
|